A Study of the Safety and Effectiveness of Canagliflozin (JNJ-28431754) in Promoting Weight Loss in Overweight and Obese Patients Who do Not Have Diabetes

Summary

The purpose of this study is to test the safety and effectiveness of JNJ-28431754 in promoting weight loss in patients who are overweight or obese and who do not have diabetes.

Timeline

Start

2008-05

Primary completion

2008-09

Completion

2008-09

Outcome

Met primary endpoint

registry analysis (superiority or other test); Placebo vs Canagliflozin 50 mg; p = 0.031; Least-Squares Mean Difference -0.9 (95% CI -1.6 to -0.1); ANOVA NCT00650806 ↗

registry analysis (superiority or other test); Placebo vs Canagliflozin 100 mg; p <0.001; Least-Squares Mean Difference -1.6 (95% CI -2.4 to -0.8); ANOVA NCT00650806 ↗

registry analysis (superiority or other test); Placebo vs Canaglifloziin 300 mg; p <0.001; Least-Squares Mean Difference -1.4 (95% CI -2.1 to -0.6); ANOVA NCT00650806 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CANAGLIFLOZIN ANHYDROUS	Small molecule	50 mg	Oral
Subject	CANAGLIFLOZIN ANHYDROUS	Small molecule	100 mg	Oral
Subject	CANAGLIFLOZIN ANHYDROUS	Small molecule	300 mg	Oral

Indications